Sitagliptin Plus Metformin In Achieve Significant Glycaemic Improvements And HbA1c Goal Attainment In Patients With Type 2 Diabetes

... Data presented today at the 19th World Diabetes Congress in Cape Town demonstrated a significant mean placebo-subtracted reduction in HbA1c of 2.1% (primary analysis of all patients treated, pMSD's Commitment to Diabetes??MSD's clinical development program for sitagliptin is robust and continues to expand with 43 studies completed or under way, and four more studies set to begin this year. [click link for full article] ...